Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CAO Robert F. Werner sold 1,448 shares of the business's stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the transaction, the chief accounting officer now owns 45,620 shares of the company's stock, valued at $2,034,652. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Twist Bioscience Price Performance
NASDAQ:TWST opened at $45.40 on Friday. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of -11.88 and a beta of 1.78. The business has a fifty day moving average price of $43.69 and a 200-day moving average price of $45.54. Twist Bioscience Co. has a one year low of $15.85 and a one year high of $60.90.
Analysts Set New Price Targets
A number of equities analysts have weighed in on TWST shares. Evercore ISI boosted their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Leerink Partners boosted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a report on Thursday, October 17th. Robert W. Baird lifted their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an "outperform" rating in a research report on Monday, August 5th. JPMorgan Chase & Co. increased their price target on Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a report on Monday, August 5th. Finally, Barclays cut their price objective on Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and an average target price of $51.22.
Financial Prophecy
From Porter & Company | Ad
The Magnificent 7 could be in for a world of pain…
And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock.
The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on.
It’s called The Final Frontier.
Including the name of the #1 company to buy.
View Our Latest Research Report on TWST
Institutional Trading of Twist Bioscience
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Intech Investment Management LLC purchased a new position in shares of Twist Bioscience during the 3rd quarter valued at about $714,000. Jennison Associates LLC lifted its holdings in Twist Bioscience by 29.6% during the third quarter. Jennison Associates LLC now owns 377,894 shares of the company's stock valued at $17,073,000 after purchasing an additional 86,399 shares in the last quarter. Thrivent Financial for Lutherans bought a new position in shares of Twist Bioscience in the third quarter worth approximately $43,992,000. Chesapeake Capital Corp IL boosted its position in shares of Twist Bioscience by 27.9% in the third quarter. Chesapeake Capital Corp IL now owns 6,176 shares of the company's stock worth $287,000 after purchasing an additional 1,347 shares during the period. Finally, Victory Capital Management Inc. increased its stake in shares of Twist Bioscience by 7.7% in the third quarter. Victory Capital Management Inc. now owns 331,809 shares of the company's stock worth $14,991,000 after purchasing an additional 23,638 shares in the last quarter.
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
